Sarepta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Well, good morning, everyone. Thanks for joining us. I'm Salveen Richter, one of the biotechnology analysts here at Goldman Sachs. We're pleased to have the Sarepta team with us today, and we have Doug Ingram, President and CEO.
Questions & Answers
So with that, Doug, you know, we've seen a rapid evolution of Sarepta over the past year and you're now positioned as a leader with multiple platforms to address neuromuscular diseases with genomic medicine, could you -- and RNA medicines as well. Can you just walk us through how you think about the next 5 years for Sarepta?
Sure. I should say, in fairness to our lawyers they are happy, that we -- obviously, this is a perfect example. I'll be making some forward-looking statements and obviously, I would ask people to look to our public
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
